Literature DB >> 11705488

Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study.

J Rehm1, P Gschwend, T Steffen, F Gutzwiller, A Dobler-Mikola, A Uchtenhagen.   

Abstract

BACKGROUND: Heroin-assisted substitution treatment for severely opioid-dependent drug users has been available in Switzerland since 1994. Our aim was to ascertain the feasibility, safety, and efficacy of this treatment.
METHODS: We did a cohort study in 21 community outpatient treatment centres. We assessed 1969 opioid-dependent drug users, who began heroin-assisted substitution treatment between January, 1994, and December, 2000, to ascertain admission and discharge patterns, and patient characteristics. We also followed up a subset of 237 patients who began treatment between Jan 1, 1994, and March 31, 1995, and who stayed with the programme for at least 18 months. We used questionnaires, interviews, and medical examinations done at entry and after 6, 12, and 18 months to assess somatic and mental health, social integration, and treatment outcomes.
FINDINGS: More than 70% (1378) of patients remained in treatment for more than a year. Treatment showed positive effects with respect to health and social outcomes. A long stay in treatment was related to a higher chance of starting abstinence-oriented therapy than a short stay.
INTERPRETATION: Heroin-assisted substitution treatment might be an effective option for chronically addicted patients for whom other treatments have failed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705488     DOI: 10.1016/S0140-6736(01)06529-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  Have we learned anything after 20 years of AIDS? Call for a national health board.

Authors:  D P Francis
Journal:  Public Health Rep       Date:  2001 Sep-Oct       Impact factor: 2.792

Review 2.  Heroin maintenance for chronic heroin-dependent individuals.

Authors:  Marica Ferri; Marina Davoli; Carlo A Perucci
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

3.  [Experimental heroin maintenance programmes: the distance between what might be done and what is really done].

Authors:  J Trujols Albet; M Casas Brugué; J Pérez de los Cobos Peris
Journal:  Aten Primaria       Date:  2002-09-15       Impact factor: 1.137

4.  Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Authors:  Benedikt Fischer; Jürgen Rehm; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady El-Guebaly; Lina Noël; Mark Tyndall; Cameron Wild; Phil Mun; Dolly Baliunas
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

5.  Why we object to NAOMI. Heroin maintenance in Canada.

Authors:  Meldon Kahan; Anita Srivastava; Kay Shen
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

Review 6.  Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics.

Authors:  Benedikt Fischer; Eugenia Oviedo-Joekes; Peter Blanken; Christian Haasen; Jürgen Rehm; Martin T Schechter; John Strang; Wim van den Brink
Journal:  J Urban Health       Date:  2007-07       Impact factor: 3.671

7.  Should heroin be prescribed to heroin misusers? Yes.

Authors:  Jürgen Rehm; Benedikt Fischer
Journal:  BMJ       Date:  2008-01-12

8.  Substance misuse: More than a quick fix.

Authors:  Tony Sheldon
Journal:  BMJ       Date:  2008-01-12

9.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

10.  Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Authors:  Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Aslam H Anis; Robert S Hogg; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.